Health Care·Biotechnology·$4.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.18 | N/A | +239.62% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.18 | N/A | +239.62% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. They remain focused on long-term growth.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline and delivering value.
Amicus Therapeutics reported a strong earnings surprise with an EPS of $0.18, significantly exceeding expectations. The stock reacted positively, rising 1.47%. However, the lack of revenue data and forward guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Nov 3, 2025